Insmed shareholders elect four Class III directors and approve 2019 Incentive Plan amendment

Proposal 3. Ratification of the Appointment of an Independent Registered Public Accounting Firm. By the following vote, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024: For Against Abstentions 135,507,026 4,170,279 61,773

Proposal 4. Approval of Amendment No. 1 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. By the following vote, shareholders approved Amendment No. 1 to the 2019 Incentive Plan: For Against Abstentions Broker Non-Votes 122,169,823 6,589,414 56,760 10,923,081

Proposal 1. Election of Four Class III Directors. By the following votes, shareholders elected David R. Brennan, Leo Lee, Carol A. Schafer, and Melvin Sharoky, M.D. to serve as Class III directors until the Company’s 2027 Annual Meeting of Shareholders: For Withheld Broker Non-Votes David R. Brennan 120,537,761 8,278,236 10,923,081 Leo Lee 125,634,442 3,181,555 10,923,081 Carol A. Schafer 113,910,394 14,905,603 10,923,081 Melvin Sharoky, M.D. 117,140,717 11,675,280 10,923,081

Proposal 2. Advisory Vote on the 2023 Compensation of Named Executive Officers. By the following vote, shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers, as disclosed in the Proxy Statement: For Against Abstentions Broker Non-Votes 120,643,045 8,076,144 96,808 10,923,081